Loading clinical trials...
Loading clinical trials...
Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Conditions
Interventions
AXT107 Low Dose
AXT107 Mid Dose
+1 more
Locations
4
United States
New England Retina Consultants
Springfield, Massachusetts, United States
The Retina Institue
St Louis, Missouri, United States
Asheville Eye Associates
Asheville, North Carolina, United States
Erie Retina Research
Erie, Pennsylvania, United States
Start Date
December 19, 2023
Primary Completion Date
March 1, 2025
Completion Date
May 1, 2025
Last Updated
May 6, 2024
NCT07308639
NCT06439576
NCT05562947
NCT05904028
NCT06213038
NCT06492863
Lead Sponsor
AsclepiX Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions